Matthijs Sevenois

Matthijs Sevenois serves as a Researcher in the Department of Nuclear Medicine at the University Hospital Brussels (UZB), affiliated with Vrije Universiteit Brussel (VUB). His work centers on radiopharmaceutical development, with a focus on alpha-emitting radionuclides and antibody-based imaging agents.

His academic background includes:

• Master's Thesis: "Preclinical quantitative imaging of $$^{225}\text{Ac}$$: a feasibility study" (2019), supervised by Prof. P. Covens and Prof. J. Heemskerk at VUB.

Research interests span multiple domains in nuclear medicine and radiochemistry:

• Development of radiolabeled nanobodies and minibodies for PET imaging
• Targeted alpha therapy using $$^{211}\text{At}$$
• Novel methods for radionuclide recovery and radiolabeling
• Noninvasive imaging of immune checkpoints in oncology
• Preclinical evaluation of theranostic radiopharmaceuticals

His recent publications demonstrate a cohesive research trajectory centered on advancing alpha-particle emitting radiopharmaceuticals, particularly leveraging $$^{211}\text{At}$$, and exploring nanobody-based imaging probes for immuno-oncology applications. This work bridges radiochemistry, molecular imaging, and cancer therapy, contributing to the growing field of precision nuclear medicine.

Scientific recognition for his work includes:

• 143 readers on Mendeley
• Reference in 1 patent
• Coverage by 17 news outlets

Sevenois is an active collaborator within a dynamic research group that includes specialists in antibody engineering, nuclear pharmacy, and oncology. His conference presentations and joint publications reflect a strong commitment to interdisciplinary research aimed at improving radiopharmaceutical therapies for cancer patients.